Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months

Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months

Annual-Meeting

5 months
111 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael Ciesielski, Phd @mjciesielski Of Roswell Park Comprehensive Cancer Center Discusses Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months. CHICAGO With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM are sharing research results at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), reporting that combination therapy with the vaccine was more effective than standard therapy for nearly all patients. The meeting, which continues through June 4 at McCormick Place in Chicago, Illinois, is the largest clinical cancer research meeting in the world. SurVaxM was developed at Roswell Park Comprehensive Cancer Center by Robert Fenstermaker, MD, Chair of Neurosurgery, and Michael Ciesielski, PhD, Assistant Professor of Neurosurgery. The vaccine is a new and unique cancer immunotherapy designed to stimulate a multifaceted immune response targeting survivin, a tumor-survival antigen not generally present in nonmalignant cells. In this five-center, single-arm phase II clinical trial (NCT identifier no. 024455557), 63 patients with newly diagnosed glioblastoma (nGBM), median age 60, were followed for safety, six-month progression-free survival, 12-month overall survival and immunologic response. All patients underwent standard treatment, involving craniotomy, radiation and treatment with temozolomide both before and after surgery. Immune response was assessed by detection of a survivin-specific antibody and CD8+ T-cell levels. The team reports that, compared to a historical analysis of patients receiving standard therapy alone, combination therapy with SurVaxM generated encouraging efficacy and immunogenicity in patients with newly diagnosed glioblastoma, with minimal toxicity or side effects. The vast majority of patients 96.8% did not experience disease progression within six months of treatment, and 93.5% were alive a year after diagnosis, compared to expected 65% survival based on historical comparisons. We essentially saw significant increase in both progression-free and overall survival, which is noteworthy in patients with such a notoriously aggressive and treatment-resistant disease, says Dr. Fenstermaker, senior author on the study. We were especially pleased to see that even patients with poor prognostic factors like high levels of survivin responded well to this combination of standard therapy plus SurVaxM, adds Dr. Ciesielski, who will present these findings in a poster presentation during the ASCO Annual Meeting. The results will also be highlighted in a poster discussion by first author Manmeet Ahluwalia, MD, Miller Family Endowed Chair in NeuroOncology at Cleveland Clinic. Researchers from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital also contributed to this research. Glioblastoma is the most common form of brain cancer in adults, and also the most aggressive. Median survival for patients treated with standard therapy is 14.7 months. SurVaxM was awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) in 2017. New studies incorporating SurVaxM are expected to open at both Cleveland Clinic and Roswell Park in the coming months. Drs. Fenstermaker and Ciesielski gratefully acknowledge donations to Roswell Park in support of their work. Dr. Ciesielski will also give an invited presentation about SurVaxM June 3 during the 2019 BIO International Convention in Philadelphia (session ID 537706) on behalf of MimiVax LLC, an early-phase Roswell Park spinoff company formed to develop the vaccine. Drs. Ciesielski and Fenstermaker are co-founders and equity shareholders in MimiVax.
Up Next Autoplay
Predicting Tumor Recurrence: How Does This Help Us?
Predicting Tumor Recurrence: How Does This Help Us?
Category: Brain Cancer
4 Views
Baylor College of Medicine 3 weeks
Predicting Tumor Recurrence
Predicting Tumor Recurrence
Category: Brain Cancer
17 Views
Baylor College of Medicine 3 weeks
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
6 Views
Cleveland Clinic 2 months
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Category: Brain Cancer
14 Views
Cleveland Clinic 2 months
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Category: Brain Cancer
14 Views
alexvarney 2 months
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Category: Brain Cancer
19 Views
alexvarney 2 months
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Category: Brain Cancer
36 Views
alexvarney 2 months
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Category: Brain Cancer
155 Views
Annual-Meeting 5 months
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Category: Brain Cancer
114 Views
Annual-Meeting 5 months
Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Category: Brain Cancer
354 Views
Annual-Meeting 5 months